Clinical Trial Search

Primary: The Visual Analog Scale (VAS) Was Used to Measures Levels of Pain. — 2; 2; 5.0 score on a scale

Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage

Primary: Efficacy: Best Objective Response Rate Percent by Treatment Group — 0; 0; 0; 0 Percent (%) of subjects

Primary: Change in Medial Knee Contact Forces During Walking — -0.04 bodyweights

Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15

Primary: Edinburgh Postnatal Depression Scale — 41; 35; 37 score on a scale

Primary: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score — 1.02; 0.80; 1.07; 1.15 Score on a scale — p=0.7975

Primary: Illicit Drug Use Days — 1.49; .80; 1.16; 0.83 days — p=.433

Primary: Number of Participants With Freedom From a Major Adverse Event (MAE) — 60 Participants

Primary: Number of Participants With Quality Skin Images Obtained From SECM Device — 15 Participants

Primary: Stage 1: Change From Baseline in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscale of…

Primary: The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC Administration — 0.810; 0.718 Probability of complete response — p=<0.05

Primary: Changes in Moderate-vigorous Intensity Physical Activity — 67.35; 4.09 min/week of physical activity

Primary: Progression-free Survival (PFS) — 23.1 percentage of participants

Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27